Gilead Sciences Slides 3.4% as Investors Digest Prior Gains and Ongoing Pricing Risks

Gilead Sciences (GILD) is down 3.4% today. Here is some analysis on what might have caused this price movement. Analysis: The catalyst is not fully clear, but the move appears tied to profit-taking after a strong post-earnings run and lingering concern around U.S. drug-pricing pressure. This could be because investors are balancing Gilead's solid HIV-driven operating momentum against policy risk and a stock price that had already moved higher in recent weeks. Details: Gilead's second-quarter 2026 update showed product sales excluding Veklury rising 10% year over year, with Biktarvy sales up 7%, reinforcing that the core business has been performing well. That same earnings release also showed a large GAAP loss tied to acquired in-process R&D and tax expenses, which can keep sentiment mixed even when underlying revenue trends are healthy. In its latest quarterly filing, Gilead said the long-term impact of U.S. most-favored-nation pricing arrangements, Medicaid model changes, tariffs, and broader trade actions remains uncertain. There does not appear to be a major new company-specific negative announcement today, so the decline may reflect valuation caution and normal volatility ahead of September healthcare investor conference presentations. Sources: Gilead Sciences, SEC, Yahoo Finance Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes. $GILD Insider Trading Activity $GILD insiders have traded $GILD stock on the open market 41 times in the past 6 months. Of those trades, 0 have been purchases and 41 have been sales. Here's a breakdown of recent trading of $GILD stock by insiders over the last 6 months: DANIEL PATRICK O'DAY (Chairman & CEO) has made 0 purchases and 14 sales selling 80,000 shares for an estimated $10,710,302 . . JOHANNA MERCIER (Chief Comm & Corp Aff Officer) has made 0 purchases and 12 sales selling 68,000 shares for an estimated $9,147,196 . . ANTHONY WELTERS has made 0 purchases and 4 sales selling 18,000 shares for an estimated $2,675,219 . . ANDREW D DICKINSON (Chief Financial Officer) has made 0 purchases and 6 sales selling 18,000 shares for an estimated $2,433,436 . . JEFFREY BLUESTONE has made 0 purchases and 5 sales selling 5,000 shares for an estimated $725,077. To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint. EARLY ACCESS Receive GILD Data Alerts Real-time alerts on filings, insider trades, and market signals — before everyone else. Get Alerts → $GILD Hedge Fund Activity We have seen 1,091 institutional investors add shares of $GILD stock to their portfolio, and 1,117 decrease their positions in their most recent quarter. Here are some of the largest recent moves: To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint. $GILD Congressional Stock Trading Members of Congress have traded $GILD stock 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales. Here's a breakdown of recent trading of $GILD stock by members of Congress over the last 6 months: REPRESENTATIVE JARED MOSKOWITZ has traded it 2 times. They made 2 purchases worth up to $30,000 on 05/06 and 0 sales. on 05/06 and 0 sales. SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/27. To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint. $GILD Price Targets Multiple analysts have issued price targets for $GILD recently. We have seen 7 analysts offer price targets for $GILD in the last 6 months, with a median target of $156.0. Here are some recent targets: Matthew Harrison from Morgan Stanley set a target price of $166.0 on 07/08/2026 on 07/08/2026 Gregory Renza from Truist Securities set a target price of $156.0 on 07/07/2026 on 07/07/2026 Brian Abrahams from RBC Capital set a target price of $120.0 on 07/07/2026 on 07/07/2026 Morten Herholdt from HSBC set a target price of $155.0 on 07/06/2026 on 07/06/2026 Carter Gould from Cantor Fitzgerald set a target price of $155.0 on 07/06/2026 on 07/06/2026 Michael Okunewitch from Maxim Group set a target price of $165.0 on 05/20/2026 on 05/20/2026 Geoff Meacham from Citigroup set a target price of $165.0 on 04/13/2026 This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.